Pharmaceuticals

FDA Approves Expanded Use of Almirall’s Crisiri to Treat Actinic Keratosis

bexib
By bexib 0 Min Read

Klisyri is currently available in a 350 mg package size as a topical treatment for actinic keratosis of the face or scalp.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article How to Dropship on eBay (2024 Guide)
Next Article Decision time has come for Ontario farmers struggling with unseeded land – RealAgriculture
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

What is the cause of the deterioration in profits of Commercial Bank of Cambodia?
Fintech
Australia invests US$50 million in Singapore’s blended finance initiative FAST-P
Fintech
GROB’s G350 – Machine Insider
Manufacturing
Graph: The impact of technology on global fund managers, Q4 2024
Retail & E-commerce